Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

Oncogene

Volumn 29, Issue 22, 2010, Pages 3196-3207

  Lee, Y C ^a   Huang, C F ^a,b   Murshed, M ^c   Chu, K ^c   Araujo, J C ^c   Ye, X ^a   Decrombrugghe, B ^c   Yu Lee, L Y ^d   Gallick, G E ^c   Lin, S H ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bone metastasis; Dasatinib; Osteoblast; Prostate cancer; Src family kinase

Indexed keywords

ABELSON KINASE; ALKALINE PHOSPHATASE; DASATINIB; FIBROBLAST GROWTH FACTOR 2; LUCIFERASE; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN KINASE YES; OSTEONECTIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CALVARIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL GROWTH; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENE SILENCING; HUMAN; MALE; METABOLISM; PHOSPHORYLATION; TUMOR INVASION;

ANIMALS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; OSTEOBLASTS; OSTEONECTIN; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

MUS MUSCULUS;

EID: 77953229623     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.73     Document Type: Article

References (48)

1. Araujo J, Logothetis C. (2009). Targeting Src signaling in metastatic bone disease. Int J Cancer 124: 1-6.
2. Aubin JE. (1998). Advances in the osteoblast lineage. Biochem Cell Biol 76: 899-910.
3. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE et al. (1998). Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78: 1219-1223.
4. Bellows CG, Aubin JE. (1989). Determination of numbers of osteoprogenitors present in isolated fetal rat calvaria cells in vitro. Dev Biol 133: 8-13.
5. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al. (2006). Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354: 2006-2013.
6. Bhargava U, Bar-Lev M, Bellows CG, Aubin JE. (1988). Ultra-structural analysis of bone nodules formed in vitro by isolated fetal rat calvaria cells. Bone 9: 155-163.
7. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. (1992). Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90: 1622-1627.
8. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ. (2009). Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 23: 590-594.
9. Canalis E, Centrella M, McCarthy T. (1988). Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 81: 1572-1577.
10. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. (1989). pp60c-src activation in human colon carcinoma. J Clin Invest 83: 2025-2033.
11. Cartwright CA, Meisler AI, Eckhart W. (1990). Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 87: 558-562.
12. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY et al. (2007). A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67: 6544-6548.
13. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. (2005). Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65: 8274-8285.
14. Debiais F, Lemonnier J, Hay E, Delannoy P, Caverzasio J, Marie PJ. 2001)). Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts. J Cell Biochem 81: 68-81.
15. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. (1999a). FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 18: 2755-2761.
16. Dorkin TJ, Robinson MC, Marsh C, Neal DE, Leung HY. (1999b). aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol 189: 564-569.
17. Fakhry A, Ratisoontorn C, Vedhachalam C, Salhab I, Koyama E, Leboy P et al. (2005). Effects of FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. Bone 36: 254-266.
18. Franceschi RT, Iyer BS. (1992). Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. J Bone Miner Res 7: 235-246.
19. Globus RK, Patterson-Buckendahl P, Gospodarowicz D. (1988). Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factor beta. Endocrinology 123: 98-105.
20. Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD et al. (2009). Effects of the Src kinase inhibitor saracatinib (AZD 0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. J Bone Miner Res (e-pub ahead of print 14 December 2009).
21. Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. (2003). Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134: 221-226. (Pubitemid 37070342)
22. Jacob K, Webber M, Benayahu D, Kleinman HK. (1999). Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 59: 4453-4457.
23. Kopetz S, Shah AN, Gallick GE. (2007). Src continues aging: current and future clinical directions. Clin Cancer Res 13: 7232-7236.
24. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. (2009). Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 101: 263-268.
25. Li B, Boast S, de los Santos K, Schieren I, Quiroz M, Teitelbaum SL et al. (2000). Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet 24: 304-308.
26. Li Z, Mathew P, Yang J, Starbuck M-W, Zurita AJ, Liu J et al. (2008). Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. J Clin Invest 118: 2697-2710.
27. Lin S-H, Cheng CJ, Lee Y-C, Ye X, Tsai W-W, Kim J et al. (2008). A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27: 5195-5203.
28. Logothetis C, Lin S-H. (2005). Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5: 21-28.
29. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. (2004). Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661.
30. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. (1993). Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 90: 4485-4489.
31. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S et al. (2000). Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151: 311-320.
32. Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H. (2003). Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54: 268-274.
33. Mayahara H, Ito T, Nagai H, Miyajima H, Tsukuda R, Taketomi S et al. (1993). in vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 9: 73-80.
34. McCarthy TL, Centrella M, Canalis E. (1989). Effects of fibroblast growth factors on deoxyribonucleic acid and collagen synthesis in rat parietal bone cells. Endocrinology 125: 2118-2126. (Pubitemid 19258650)
35. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R et al. (2005). Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185-9189.
36. Nelson JB, Hedican SP, George AH, Reddi AH, Piantadosi S, Eisenberger MA et al. (1995). Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1: 944-949.
37. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW et al. (1999). New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53: 1063-1069.
38. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY et al. (2008). Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68: 3323-3333.
39. Rossert J, Eberspaecher H, de Crombrugghe B. (1995). Separate cis-acting DNA elements of the mouse pro-alpha 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J Cell Biol 129: 1421-1432.
40. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
41. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC et al. (2007). Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67: 2800-2808.
42. Soriano P, Montgomery C, Geske R, Bradley A. (1991). Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693-702.
43. Stein GS, Lian JB. (1993). Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14: 424-442.
44. Summy JM, Gallick GE. (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358.
45. Talamonti MS, Roh MS, Curley SA, Gallick GE. (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60.
46. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY et al. (2006). Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarci-noma cells in an orthotopic nude mouse model. Am J Pathol 168: 962-972.
47. Vakar-Lopez F, Cheng C-J, Kim J, Shi GG, Troncoso P, Tu S-M et al. (2004). Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203: 688-695.
48. Ye XC, Choueiri M, Tu SM, Lin SH. (2007). Biology and clinical management of prostate cancer bone metastasis. Front Biosci 12: 3273-3286.